KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inovio Pharmaceuticals (INO) Research & Development (2016 - 2025)

Inovio Pharmaceuticals' Research & Development history spans 16 years, with the latest figure at $13.3 million for Q3 2025.

  • For Q3 2025, Research & Development fell 28.83% year-over-year to $13.3 million; the TTM value through Sep 2025 reached $56.8 million, down 28.95%, while the annual FY2024 figure was $75.6 million, 12.76% down from the prior year.
  • Research & Development for Q3 2025 was $13.3 million at Inovio Pharmaceuticals, down from $14.5 million in the prior quarter.
  • Across five years, Research & Development topped out at $92.3 million in Q4 2021 and bottomed at $12.9 million in Q4 2024.
  • The 5-year median for Research & Development is $23.7 million (2023), against an average of $33.8 million.
  • The largest annual shift saw Research & Development skyrocketed 250.91% in 2021 before it tumbled 59.04% in 2023.
  • A 5-year view of Research & Development shows it stood at $92.3 million in 2021, then crashed by 54.37% to $42.1 million in 2022, then crashed by 59.04% to $17.3 million in 2023, then fell by 25.31% to $12.9 million in 2024, then grew by 3.48% to $13.3 million in 2025.
  • Per Business Quant, the three most recent readings for INO's Research & Development are $13.3 million (Q3 2025), $14.5 million (Q2 2025), and $16.1 million (Q1 2025).